Article
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
European journal of cancer (Oxford, England : 1990) - 1 Dec 2021
Patsouris Anne, Diop Kadija, Tredan Olivier, Nenciu Daniel, Gonçalves Anthony, Arnedos Monica, Sablin Marie-Paule, Jézéquel Pascal, Jimenez Marta, Droin Nathalie, Bièche Ivan, Callens Céline, Loehr Andrea, Vicier Cécile, Guerin Catherine, Filleron Thomas, André Fabrice
Abstract excerpt
BACKGROUND: Breast cancer may present genomic alterations leading to homologous recombination deficiency (HRD). PARP inhibitors have proven their efficacy in patients with HER2-negative (HER2-) metastatic breast cancer (mBC) harbouring germline (g) BRCA1/2 mutations in 3 phases III trials. The single-arm phase II RUBY trial included 42 patients, 40 of whom received at least one dose of rucaparib. RUBY study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.